SCHEMBL959196

SCHEMBL959196

CCCNc1cccc2ccccc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.67
CA4 P22748 2/20 0.67
CA7 P43166 2/20 0.67
CA9 Q16790 2/20 0.67
CA14 Q9ULX7 2/20 0.67
CA3 P07451 1/20 0.67
CA6 P23280 1/20 0.67
CA5A P35218 1/20 0.67
CA5B Q9Y2D0 1/20 0.67
ALDH1A1 P00352 6/20 0.65
TSHR P16473 3/20 0.65
HSD17B10 Q99714 3/20 0.65
RECQL P46063 1/20 0.65
HPGD P15428 5/20 0.61
KDM4E B2RXH2 5/20 0.61
MAPT P10636 3/20 0.61
GAA P10253 3/20 0.61
EPHX1 P07099 1/20 0.58
IDO1 P14902 1/20 0.58
KEAP1 Q14145 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31268310 1.00 CA12 (0.67) CA12CA4CA7CA9CA14
SCHEMBL731902 0.89 ALDH1A1 (0.67) CA12CA4CA7CA9CA14
SCHEMBL30301306 0.89 ALDH1A1 (0.67) CA12CA4CA7CA9CA14
SCHEMBL11509092 0.87 IDO1 (0.66) CA12CA4CA7CA9CA14
SCHEMBL11283741 0.87 CA12 (0.77) CA12CA4CA7CA9CA14
SCHEMBL2234377 0.87 KDM4E (0.70) CA12CA4CA7CA9CA14
SCHEMBL31268288 0.87 KDM4E (0.70) CA12CA4CA7CA9CA14
SCHEMBL16466615 0.85 ALDH1A1 (0.68) CA12CA4CA7CA9CA14
SCHEMBL3690951 0.85 ALDH1A1 (0.68) CA12CA4CA7CA9CA14
SCHEMBL4785065 0.85 ALDH1A1 (0.68) CA12CA4CA7CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027148-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS BEXSON BIOMEDICAL INC (US) 2026-01-29 US claimed
US-20260014191-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS BEXSON BIOMEDICAL INC (US) 2026-01-15 US claimed
EP-4444283-A1 SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT Tactogen Inc. (US) 2024-10-16 EP claimed
US-20240226110-A1 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION APNIMED, INC. (DELAWARE) 2024-07-11 US claimed
WO-2024027767-A1 HERBICIDE COMPOSITION COMPRISING URACIL COMPOUND COMPRISING CARBOXYLATE FRAGMENT AND USE OF HERBICIDE COMPOSITION 江苏中旗科技股份有限公司 2024-02-08 WO claimed
WO-2023107715-A1 SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT TACTOGEN INC (US) 2023-06-15 WO claimed
WO-2023278597-A1 5-HT2C AGONISTS FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION APNIMED, INC. (DELAWARE) (US) 2023-01-05 WO claimed
CN-108896694-B A kind of remaining LC-QToF-MS Screening analysis method of pesticide in animal food 中国农业科学院农业质量标准与检测技术研究所 2019-09-27 CN claimed
CN-108896694-A A kind of remaining LC-QToF-MS Screening analysis method of pesticide in animal food 中国农业科学院农业质量标准与检测技术研究所 2018-11-27 CN claimed
CN-106573900-A Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto 美国陶氏益农公司 2017-04-19 CN claimed
CN-106231904-A Comprise the Herbicidal combination of piperazine class 巴斯夫欧洲公司 2016-12-14 CN claimed
CN-1589101-A Herbicides containing substituted thien-3-ylsulfonylamino (thio) carbonyltriazolin (thi) one compounds BAYER CROPSCIENCE GMBH (DE) 2005-03-02 CN claimed
CN-1391439-A Synergistic herbicidal active substance combinations BAYER AG (DE) 2003-01-15 CN claimed
US-5266207-A Composite nanofiltration membrane TECHSEP (FR) 1993-11-30 US claimed
US-12599578-B2 Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof Ensysce Biosciences Inc. (US) 2026-04-14 US disclosed
EP-4694606-A1 RADIO WAVE SHIELDING BODY AND ADHESIVE COMPOSITION Zeon Corporation (JP) 2026-02-11 EP disclosed
EP-4079311-B1 NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM NUVAMID SA (CH) 2025-10-01 EP disclosed
US-4304718-A ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-12-08 US disclosed
US-4268438-A Cationic 1,3,4-thiadiazole dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1981-05-19 US disclosed
US-4181800-A ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014191-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS SLC6A4, SLC6A3, SIGMAR1 CA12 1196/4885CA4 2313/4885CA7 2534/4885
US-20260027148-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS SLC6A3, SIGMAR1, SLC6A4 CA12 1615/4885CA4 2547/4885CA7 2788/4885
US-12599578-B2 Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof OPRK1, OPRL1, OPRM1 CA12 842/4885CA4 542/4885CA7 563/4885
US-20240226110-A1 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION HTR2C, HTR5A, HTR1A CA12 4029/4885CA4 3925/4885CA7 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.